Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

7.480 +0.060 (+0.81%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist

Price and Volume

Volume	1,775,614
Open	7.370
Bid (Size)	7.470 (84)
Ask (Size)	7.480 (75)
Prev. Close	7.420
Today's Range	7.355 - 7.610
52wk Range	5.590 - 9.475
Shares Outstanding	1,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

2 Reasons to Avoid AMRX and 1 Stock to Buy Instead

April 24, 2025

Over the past six months, Amneal’s shares (currently trading at $6.85) have posted a disappointing 17.6% loss while the S&P 500 was down 8.1%. This might have investors contemplating their next move.

Via StockStory

3 of Wall Street’s Favorite Stocks That Concern Us

April 11, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Performance

YTD	-3.6%	-3.6%
1 Month	-10.5%	-10.5%
3 Month	-13.8%	-13.8%
6 Month	-11.0%	-11.0%
1 Year	+26.8%	+26.8%

More News

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month

April 11, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal to Report First Quarter 2025 Results on May 2, 2025

April 08, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients

April 07, 2025

Via Benzinga

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

April 07, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

April 03, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

April 01, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

March 13, 2025

Via StockStory

Amneal to Participate at Upcoming Investor Conference

March 10, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

March 05, 2025

Via StockStory

Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

March 03, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars

February 28, 2025

Via Benzinga

Amneal’s (NASDAQ:AMRX) Q4 Sales Beat Estimates, Guides for Strong Full-Year Sales

February 28, 2025

Via StockStory

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

February 28, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For February 28, 2025

February 28, 2025

Via Benzinga

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 27, 2025

Via StockStory

Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock

February 24, 2025

Via Benzinga

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

February 21, 2025

Via StockStory

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

February 19, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

February 19, 2025

Via StockStory

Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks

February 14, 2025

Via StockStory

ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group

February 13, 2025

Via StockStory

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

January 29, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

January 23, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Amneal Pharmaceuticals, Inc. - Class A Common Stock publicly traded?

Yes, Amneal Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.

What exchange does Amneal Pharmaceuticals, Inc. - Class A Common Stock trade on?

Amneal Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock?

The ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock is AMRX on the Nasdaq Stock Market

What is the current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock?

The current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 7.480

When was Amneal Pharmaceuticals, Inc. - Class A Common Stock last traded?

The last trade of Amneal Pharmaceuticals, Inc. - Class A Common Stock was at 04/25/25 04:00 PM ET

What is the market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock?

The market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 7.48K

How many shares of Amneal Pharmaceuticals, Inc. - Class A Common Stock are outstanding?

Amneal Pharmaceuticals, Inc. - Class A Common Stock has 7K shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.